Maybe they’re churning out DIMI’s as we speak. They said themselves that there's a market for it. Clearly they believed in it enough to get FDA approval to sell it. Let's see them capture at least 0.05% of the market share with DIMI in long term care homes.
Who cares about home use if you can't even sell it to all these 'eagerly waiting' customers. It's time to capitalize on the fruits of your labour and the pitch you gave to investors to risk their money.
There was a muted response to the share price after DIMI got approval, I think the market questions how capable the company is of selling it. Surprise everyone and watch the share price sky rocket. Or sell it/license it to someone? If the reason you can't is that no one wants to sell it and no one wants to license it... why do it?
As the company puts it in the excerpt from the news release below, there are 15 600 skilled nursing facilities with more than a million patients. Seems like more than enough for the current size of the company. With that many potential customers I'd think we would be expecting them to raise money on the back of a facility expansion because of sales orders they're having trouble filling.
If not, why is home use going to be any different? Are there droves of people sitting at home waiting for this device? Why would they buy it from spectral? Will our sales force be able to get through to them DIMI is the best? How will they do it? Is there a sales plan for this product that's better than the other products the company currently sells?
guess a lot of questions to ask during the investor conference.
Current DIMI Market Opportunities:
As Dialco prepares to extend the indication for DIMI to include both home and PD use, Dialco will focus on the chronic dialysis centers and long-term care facilities markets. These segments offer promising markets where DIMI can offer unique advantages over current products in this space.
- According to the CDC, there are approximately 15,600 skilled nursing facilities (“SNFs”) in the U.S. providing care to approximately 1.7 million residents;
- An estimated 74,000 dialysis patients live in SNFs, with the majority traveling to dialysis centers to receive treatment;
- Installation of easy-to-use dialysis machines in SNFs could help reduce risks of patient travel to clinics, reduce overall costs of care and provide a new source of revenue for the SNF;
- Existing U.S. SNF markets represent an estimated US$2 billion market annually (combined devices and disposables).